Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].

Nederlands tijdschrift voor geneeskunde - 19 Apr 2008

Lind J S W, Herder G J M, Smit E F

Abstract excerpt

The recently developed 'targeted' therapies, epidermal growth factor receptor (EGFR) inhibitors and angiogenesis inhibitors, target specific tumour characteristics. EGFR inhibitors, such as gefitinib and erlotinib, can lead to remission, particularly in non-small cell lung cancer (NSCLC) with specific EGFR mutations. These mutations occur more frequently in Asians, women, non-smokers and those with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Drug Therapy, Combination

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Neovascularization, Pathologic

Share to Quinazolines

Source

Identifiers

PMID: 18561788

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].PMID 18561788Read ↗

[Targeted therapies in the treatment of non-small cell lung cancer].Semantic proximity Read ↗

[Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer.Semantic proximity Read ↗

[New biological treatments for lung cancer].Semantic proximity Read ↗

[More Personalized Treatment using Diversified Molecular Targeted Therapy Strategies for EGFR Mutation-Positive Non-Small-Cell Lung Cancer-Sequential Treatment Comprising First- and Second-Line Therapy with EGFR-TKIs and Treatment Options in Combination with Anti-Angiogenic Agents].Semantic proximity Read ↗

First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.Semantic proximity Read ↗

[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].Semantic proximity Read ↗

[Small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR)].Semantic proximity Read ↗

Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced non‑small cell lung cancer with EGFR mutation (Review).Semantic proximity Read ↗

Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan.Semantic proximity Read ↗

Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.